Supernus, Inc. (SUPN) análisis del liderazgo y del equipo directivo
This article provides an analysis of Supernus, Inc.'s leadership and management team, noting that the company's CEO information is not sufficiently available and that both the management team and board are considered new due to short average tenures. It also details recent updates regarding Indivior Pharmaceuticals, Inc.'s acquisition of Supernus Pharmaceuticals, Inc., which closed on November 2, 2026, leading to the combined entity being named Supernus, Inc. and Jack Khattar becoming its President, CEO, and Director. The report includes extensive announcements about Indivior's financial performance, product developments related to SUBLOCADE, and other corporate changes leading up to and following the merger.
Form 8K Indivior Pharmaceuticals Inc For: 2 November By Investing.com
This article announces that Indivior Pharmaceuticals Inc. filed a Form 8K on November 2nd. The filing is a standard regulatory announcement that publicly traded companies make to disclose material events or information to shareholders. No further details about the content of the 8K filing are provided within the article.
Form 8K Indivior Pharmaceuticals Inc For: 2 November By Investing.com
This article reports that Indivior Pharmaceuticals Inc. filed a Form 8K on November 2nd. The brief notice from Investing.com indicates this filing is available for review, with the company's stock symbol INDV showing a 3.79% increase.
Indivior Pharmaceuticals appoints Jack A. Khattar as CEO as four executives depart
Indivior Pharmaceuticals (INDV) has appointed Jack A. Khattar as CEO and director, among other officer and director appointments, following a merger. Four existing officers and four directors have departed the company. The changes, detailed in an SEC filing, include significant separation agreements for departing executives and an employment agreement for the new CEO.
Indivior Pharmaceuticals, Inc. (INDV) Seasonal returns chart
The article provides a seasonal returns chart for Indivior Pharmaceuticals, Inc. (INDV), showing average monthly price returns from 2016 to 2026. It notes that INDV is trading under a new symbol, SUPN, effective November 3, 2026. The current stock price for INDV is listed as 36.28 USD, up 2.57%.
Indivior Pharmaceuticals, Inc. (INDV) Seasonal returns chart
The article provides a seasonal returns chart for Indivior Pharmaceuticals, Inc. (INDV), showing the average monthly price return from 2016 to 2026. It notes that INDV will be trading under the new symbol SUPN effective November 3, 2026. The current stock price is listed as 36.28, up 2.57%.
Revenue climbs 13% at Indivior (INDV), with profit rising from $42M.
Indivior Pharmaceuticals, Inc. reported a significant increase in its third-quarter 2026 net revenue to $356 million, up 13% from $314 million in the prior year, with net income soaring to $137 million from $42 million. The company also announced an agreement to sell its French and German SUBUTEX tablet business for $95 million and a special cash dividend of $1,000 million, or $8.13 per share, to be paid after its merger with Supernus Pharmaceuticals, Inc., which stockholders approved and is expected to close around November 2, 2026. Indivior also ceased all pipeline development activities and reduced operating expenses through corporate initiatives and headcount reductions.
Indivior PLC (INDV) Tops Q3 EPS by 52c; Offers Guidance
Indivior PLC (INDV) reported strong Q3 earnings, surpassing analyst estimates by $0.52 with an EPS of $1.32, and revenue of $356 million, exceeding the consensus. The company also provided its FY2026 outlook, projecting revenue between $1.29 billion and $1.36 billion.
Indivior Pharmaceuticals, Inc. (INDV) stock price, news, quote and history
This article provides a real-time snapshot of Indivior Pharmaceuticals, Inc. (INDV) stock, including its current price, daily change, and key financial statistics. It features a chart for historical data, alongside valuation measures, profitability metrics, and balance sheet highlights. The information is presented as of market open on the specified date.
Insights | DOJ Demonstrates Continued Focus on Opioid Crisis with $600 Million Criminal and Civil Settlement Against Indivior Solutions, Indivior Inc., and Indivior plc
The Department of Justice secured a $600 million criminal and civil settlement against Indivior Solutions, Inc., Indivior Inc., and Indivior plc, demonstrating its continued focus on the opioid crisis with creative penalties. The article also includes updates from September 2026 and early October 2026 on energy law, regulatory developments, litigation, legislative changes impacting data centers and environmental permitting, and recent Supreme Court activities. These insights highlight significant legal and regulatory shifts in the healthcare, energy, and environmental sectors, as well as crucial Supreme Court decisions.
Brokerages set USD 45.17 target for Indivior stock
Seven brokerages have set an average 12-month price target of USD 45.17 for Indivior, representing a 31.42 percent upside from its Nasdaq price of USD 34.37. The company's stock was trading at EUR 30.50 on October 20, 2026, and its third-quarter 2026 earnings release is scheduled for October 29.
INDV: Indivior Plc Latest Stock Price, Analysis, News and Trading Ideas
This article provides an overview of Indivior Plc (INDV), including its latest stock price, fundamental data, and recent news. Indivior is a specialty pharmaceutical company focused on opioid use disorder. Key updates include an upcoming Q3 earnings report on October 29, 2026, and the recent approval of its merger with Supernus Pharmaceuticals by shareholders.
Third-quarter results are due at 7 a.m. Oct. 29 from Indivior.
Indivior Pharmaceuticals (INDV) announced it will report its third-quarter 2026 financial results on Thursday, October 29, 2026, at 7:00 a.m. U.S. EDT. The results will be accessible on the company's website. Indivior specializes in long-acting injectable treatments for opioid use disorder (OUD).
ETF investissant dans des actions Indivior Pharmaceuticals, Inc.
This article lists various ETFs that hold shares of Indivior Pharmaceuticals, Inc., providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, and performance. It serves as a resource for investors looking to invest in Indivior Pharmaceuticals indirectly through ETFs, offering a breakdown of key financial metrics for each fund.
Brokerages set USD 45.17 target for Indivior stock
Seven research firms have set a consensus target of USD 45.17 for Indivior stock, which is 39.20 percent above its last Nasdaq price of USD 32.45. Indivior reported second-quarter revenue of USD 343.00 million. The company's market capitalization is USD 4.0 billion with a price-to-earnings ratio of 11.63.
Barclays cuts target for Indivior stock to USD 43.00
Barclays has reduced its price target for Indivior stock from USD 46.00 to USD 43.00. The specialty pharmaceutical company is set to report its next results on October 29, 2026. Indivior's stock was trading at EUR 29.90 at Lang & Schwarz on October 15, 2026, down 1.58 percent, with a market capitalization of USD 4.2 billion.
Indivior stock gains as Supernus merger and special dividend plan come into focus
Indivior stock has seen gains, closing at USD 34.77 on Nasdaq, driven by its planned all-stock merger with Supernus Pharmaceuticals and a USD 1 billion special dividend to shareholders. The company, recently rebranded as Indivior Pharmaceuticals, Inc., has a market capitalization of USD 4.10 billion, and analysts have a "Moderate Buy" rating with a consensus price target of USD 45.17. The strategic realignment towards the North American market and a U.S.-centric investor base are key aspects of its transformation.
Indivior declares a special dividend per Indivior stock
Indivior has declared a special dividend of USD 8.13 per stock, payable on November 6, 2026, contingent on the completion of the proposed Supernus Pharmaceuticals merger. This announcement follows a strong second quarter in 2026, where the company reported a 14.00 percent year-over-year revenue increase to USD 343.0 million and more than doubled its adjusted EBITDA. Indivior also raised its full-year 2026 guidance, highlighting robust operating growth alongside the strategic merger terms.
Indivior stock pre-market at EUR 32.10: plus 0.00 percent
Indivior stock remained unchanged pre-market at EUR 32.10, according to Lang & Schwarz. The company has declared a contingent special cash dividend of USD 8.13 per share, payable upon the completion of its merger with Supernus Pharmaceuticals, expected around November 2, 2026. This dividend, announced in a September 17, 2026 release, will only be paid if the merger is finalized.
Indivior stock after-hours at EUR 31.90: plus 0.63 percent versus prior close
Indivior stock closed after-hours at EUR 31.90, marking a 0.63 percent increase from its prior close. The company announced a conditional special cash dividend of USD 8.13 per share, contingent on the completion of its merger with Supernus Pharmaceuticals, expected around November 2, 2026. The Federal Trade Commission granted the transaction on September 21, 2026.
Indivior stock highlights USD 8.13 dividend plan
Indivior has declared an $8.13 special dividend, conditional on its proposed merger with Supernus. The dividend payment is anticipated around November 6, 2026, following the expected merger closing on November 2, 2026, and is subject to shareholder approvals. The company reported Q2 2026 revenue of $343.0 million, providing operating support alongside the dividend plan.
Indivior stock after-hours at EUR 31.50: plus 0.00 percent versus Lang & Schwarz prior close
Indivior stock traded at EUR 31.50 after-hours on October 2, 2026, showing no change from its Lang & Schwarz prior close. The company announced a contingent special cash dividend of USD 8.13 per share, payable upon the closing of its planned merger with Supernus Pharmaceuticals, Inc., expected around November 2, 2026. This dividend is conditional on the merger's completion, with a record date of October 30, 2026, and payment anticipated around November 6, 2026.
Indivior declares USD 8.13 dividend. Indivior stock gains 1.27 percent
Indivior has declared a conditional special cash dividend of USD 8.13 per share, dependent on the completion of its merger with Supernus Pharmaceuticals. The company also reported a 14.00 percent increase in Q2 2026 revenue to USD 343.00 million, with SUBLOCADE revenue up 21.00 percent. Indivior's stock saw a 1.27 percent gain, trading at EUR 31.90.
Indivior stock: company declares conditional USD 8.13 special dividend
Indivior Pharmaceuticals has declared a conditional special cash dividend of USD 8.13 per share. This payment is contingent upon the successful completion of its proposed merger with Supernus Pharmaceuticals. If the merger, expected around November 2, 2026, closes as planned, the dividend will be paid on or about November 6, 2026, to shareholders of record as of October 30, 2026.
Indivior stock last trades at USD 36.88 on September 28, 2026
Indivior shares closed at USD 36.88 on Nasdaq on September 28, 2026, marking a 2.96% increase from the previous day's close. The company had previously declared a conditional special cash dividend of USD 8.13 per share, contingent on the successful merger with Supernus Pharmaceuticals, expected to close around November 2, 2026. If the merger is completed, the dividend is anticipated to be paid around November 6, 2026.
Indivior Pharmaceuticals Inc (INDV-Q) Stock Price and News
This article provides financial news and stock performance data for Indivior Pharmaceuticals Inc. (INDV-Q), listed on NASDAQ. It includes recent news headlines focusing on the company's merger activities with Supernus, earnings reports, and analyst ratings, alongside its company profile and stock-related metrics.
Indivior stock at USD 35.82 on September 25, 2026
Indivior stock was last quoted at USD 35.82 on September 25, 2026. The company has declared a conditional special cash dividend of USD 8.13 per share, payable upon the closing of its proposed merger with Supernus Pharmaceuticals, Inc., which is expected around November 2, 2026. The stock was down 0.50 percent from its previous close on Nasdaq under the ticker INDV.
INDV IMPORTANT DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Indivior PLC Investors with Losses in Excess of $100K to Secure Counsel Before Important October 1 Deadline in Securities Class Action - INDV
The Rosen Law Firm is encouraging investors of Indivior PLC (NASDAQ: INDV) who incurred losses exceeding $100,000 to join a securities class action lawsuit. The deadline to serve as lead plaintiff is October 1, 2024. The lawsuit alleges that Indivior made false and misleading statements about its business, operations, and financial prospects, particularly concerning the impact of legislation on its products and its revenue guidance for Fiscal Year 2024.
Indivior stock carries a USD 8.13 special dividend
Indivior stock announced a USD 8.13 special dividend, contingent on the completion of its merger with Supernus Pharmaceuticals, which is expected to close on November 2, 2026. The record date for the dividend is October 30, 2026, with payment anticipated on November 6, 2026. The company also reported strong Q2 2026 financial results, with revenue up 14% year-over-year, and analysts maintain a "Moderate Buy" rating with a target price significantly above its current trading value.
Indivior stock heads into the open after a 0.14 percent fall
Indivior stock closed at USD 35.86 on September 24, 2026, marking a 0.14 percent decline with a trading volume of 50,261 shares. A rights-related announcement was made today, indicating that Addex Therapeutics has regained full global rights to certain GABAB positive allosteric modulator assets from Indivior UK Limited, following Indivior's rationalization of R&D and a planned merger with Supernus Pharmaceuticals. This announcement is expected to influence the stock's performance in the upcoming session.
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
Addex Therapeutics has reacquired full global rights to its GABAB positive allosteric modulator (PAM) assets from Indivior UK Limited. This decision by Indivior to rationalize R&D activities and a planned merger with Supernus Pharmaceuticals, Inc. led to the return of these rights. Addex now has the flexibility to independently advance its GABAB PAM portfolio, including the returned candidate for substance use disorders and its proprietary candidate for chronic cough, allowing exploration of various strategic options.
Indivior stock heads into the open after a 0.77 percent drop
Indivior stock closed down 0.77 percent at USD 35.91 on Nasdaq on September 23, 2026, underperforming the Nasdaq Composite which fell 1.13 percent. The company's stock is currently 15.9 percent below its 52-week high but USD 13.46 above its 52-week low. Indivior has also declared an USD 8.13 special dividend tied to a planned merger with Supernus Pharmaceuticals, with a record date of October 30, 2026, and a payment date of November 6, 2026.
Indivior Pharmaceuticals stock reports USD 8.13 special dividend
Indivior Pharmaceuticals has declared a special dividend of USD 8.13 per share, contingent on its planned merger with Supernus Pharmaceuticals. The company also reported strong Q2 2026 results, with revenue up 13.6% to USD 343 million and adjusted EPS rising 125.5% to USD 1.15, leading to an increased full-year revenue guidance. The dividend is payable to shareholders of record on October 30, 2026, with payment scheduled for November 6, 2026, making the merger's completion a critical value driver for existing shareholders.
Indivior stock heads into the open after closing at USD 34.88
Indivior stock closed at USD 34.88 on the Nasdaq on September 20, 2026, with a reported market capitalization of USD 4.4 billion. This closing price represented approximately 77.2% of the average analyst target of USD 45.17. The article provides financial data for Indivior PLC (ISIN GB00BYZ0C031).
Indivior stock stands at USD 34.88 below analyst targets
Indivior stock traded at USD 34.88 on September 20, 2026, which is USD 10.29 below the average analyst target of USD 45.17, implying a 29.5% difference. The company's market capitalization was USD 4.4 billion on the same date. This discrepancy highlights the gap between the market's valuation and analysts' expectations for Indivior.
Indivior stock heads into the open after a flat Nasdaq close
Indivior stock closed at USD 34.88 on Nasdaq on September 18, 2026, remaining flat against the previous session and broadly aligning with the healthcare sector's modest movements. Analysts currently hold a "Moderate Buy" consensus with an average 12-month price target of USD 45.17, indicating potential undervaluation compared to its market price and a model-derived fair value of USD 40.63. Investors are focusing on these analyst views and valuation metrics as the new trading day begins, with no specific company events scheduled.
Indivior (INDV) Receives a Rating Update from a Top Analyst
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Indivior (INDV). The company reported a quarterly revenue of $343 million and a net profit of $122 million for the quarter ending June 30. Corporate insider sentiment is positive, with an increase in insider buying over the past quarter.
Indivior declares $8.13 contingent special dividend
Indivior Pharmaceuticals (NASDAQ:INDV) has declared a contingent special cash dividend of $8.13 per share. This dividend is dependent on the successful completion of its merger with Supernus Pharmaceuticals. Shareholders of record as of October 30, 2026, are expected to receive payment around November 6, 2026, provided the merger closes as planned.
Form 8K Indivior PLC For: 17 September By Investing.com
This article reports that Indivior PLC filed a Form 8K on September 17, 2026. The brief announcement provides no further details on the content of the filing but mentions the company's stock symbol INDV, which was up 3.14% at the time of publication. The article is primarily a placeholder for the filing information, surrounded by general financial news and market data.
Form 8K Indivior PLC For: 15 September By Investing.com
This article from Investing.com reports that Indivior PLC filed a Form 8K for September 15. The content is primarily a placeholder or brief announcement, with the majority of the page filled with financial market data, popular news links, and various navigational elements common to a financial news platform.
Form 8K Indivior PLC For: 15 September By Investing.com
This article from Investing.com announces the filing of Form 8K by Indivior PLC for September 15. The brief piece reiterates the company name, the form filed, and the date, accompanied by its stock symbol INDV and a positive price change. It appears to be a very concise news alert about a corporate filing.
Indivior Pharmaceuticals to end supply agreement with Reckitt Benckiser in January
Indivior Pharmaceuticals will terminate its supply agreement with Reckitt Benckiser Healthcare (UK) Limited on January 15, 2027, an accelerated termination for the manufacture of SUBOXONE and SUBUTEX tablets. Indivior has secured a new supplier, and the financial implications of the termination and new agreement are not expected to be material to the company. This development follows recent news of Indivior's strong Q2 2026 results and a planned merger with Supernus Pharmaceuticals.
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
Indivior Pharmaceuticals Inc. (INDV) shares have dropped 5.3% since its last earnings report, underperforming the S&P 500. The company, however, beat Q2 2026 earnings estimates, reporting adjusted earnings of $1.15 per share and revenues of $343 million, primarily driven by strong U.S. Sublocade performance. Indivior also raised its full-year 2026 financial guidance, projecting net revenues between $1.295-$1.365 billion and adjusted EBITDA of $700-$740 million, reflecting strong commercial execution and market demand.
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Indivior Pharmaceuticals Inc. (INDV) has experienced a 12.9% decline in stock price over the past four weeks, but indicators suggest a potential trend reversal. The stock's Relative Strength Index (RSI) is in oversold territory at 28.53, and Wall Street analysts have increased their earnings estimates for the current year. Additionally, INDV holds a Zacks Rank #2 (Buy), further indicating a possible turnaround.
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Indivior Pharmaceuticals Inc. (INDV) has experienced a 12.9% decline over the past four weeks, but indicators suggest a potential trend reversal. Its Relative Strength Index (RSI) of 28.53 indicates the stock is oversold, while Wall Street analysts have raised earnings estimates, leading to a Zacks Rank #2 (Buy). These factors combined point to a possible rebound in the near term for INDV.
Indivior stock holds near $36 after a buyback run
Indivior stock has maintained a price near $36.11, boasting high profitability margins and significant revenue and EPS growth. Despite recent insider sales, the company's strong financial health, modest debt, and core products like SUBLOCADE and SUBOXONE Film suggest continued performance tied to operational execution. The stock remains above its 200-day moving average and has seen a 53.31% gain over the last 12 months.
Indivior stock holds firm after record quarter and Supernus merger plan
Indivior Plc's stock is trading at an elevated level following a record quarter and the announcement of a planned merger with Supernus. The company reported record revenue and profit, driven by its opioid use disorder treatments, with a P/E ratio of 13 and a market capitalization of $4.6 billion. The Supernus merger aims to diversify Indivior's neuroscience-related treatments and sustain future growth, with investors evaluating the integration risks against the strong financial performance.
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan
Indivior Pharmaceuticals (INDV) is considered significantly undervalued, trading at a discount to analyst targets and intrinsic value, despite a recent 9% monthly dip. The company's "Action Agenda," aiming to reduce non-essential spending by at least US$150 million annually and cap 2026 operating expenses at US$450 million, is expected to boost adjusted EBITDA and free cash flow. This strategy, coupled with anticipated strong SUBLOCADE uptake, supports a fair value estimate of $53.00, suggesting a 30.4% undervaluation.
Reasons Why Investors Should Consider Betting on Indivior Stock
Indivior Pharmaceuticals (INDV) is positioned as a strong investment due to the commercial success of its opioid use disorder treatment, Sublocade, which has seen significant adoption and market share growth. The company also demonstrates disciplined capital allocation by focusing on high-value opportunities and implementing cost-optimization programs. Indivior currently holds a Zacks Rank #1 (Strong Buy), with positive earnings per share estimates for 2026 and 2027.
Indivior stock holds firm as Supernus merger and higher 2026 EBITDA outlook reshape the story
Indivior stock is currently being evaluated by investors in light of a proposed merger with Supernus Pharmaceuticals and an upgraded 2026 adjusted EBITDA outlook ranging from $700 million to $740 million. The company's key product, Sublocade, continues to drive significant revenue growth and patient adoption, contributing to increased profitability. While valuation metrics present a mixed picture of premium sales multiples and discounted fair value estimates, the potential Supernus merger is expected to further broaden Indivior's pipeline and substantially increase pro forma revenues and EBITDA.